Urologix, Inc. (ULGX)
- Previous Close
0.0001 - Open
0.0001 - Bid --
- Ask --
- Day's Range
0.0001 - 0.0001 - 52 Week Range
0.0000 - 0.0002 - Volume
250 - Avg. Volume
0 - Market Cap (intraday)
82,907 - Beta (5Y Monthly) -76.60
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Urologix, Inc. develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia (BPH) in the United States. The company offers Cooled ThermoTherapy, which produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. It also provides Prostiva RF Therapy System that delivers radio frequency energy directly into the prostate to destroy prostate tissue, reduce constriction of the urethra, and relieve BPH symptoms. It serves patients and clinicians. Urologix, Inc. was founded in 1991 and is based in Minneapolis, Minnesota.
www.urologix.comRelated News
Performance Overview: ULGX
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ULGX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ULGX
Valuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
0.40
Enterprise Value/EBITDA
-9.52
Financial Highlights
Profitability and Income Statement
Profit Margin
-38.90%
Return on Assets (ttm)
-7.62%
Return on Equity (ttm)
--
Revenue (ttm)
12M
Net Income Avi to Common (ttm)
-4.67M
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
492k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
725.88k
Company Insights: ULGX
ULGX does not have Company Insights